You just read:

Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock

News provided by

Sangart, Inc.

May 24, 2012, 12:00 ET